share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 21 04:43
Summary by Futu AI
RedHill Biopharma Ltd. has announced the postponement of its Extraordinary General Meeting of Shareholders, which was originally scheduled for March 20, 2024. The adjournment was due to the absence of the required legal quorum. The meeting has been rescheduled to take place the following day, March 21, 2024, at 3:00 p.m. Israel time at the company's office in Tel Aviv. This information was disclosed in a Form 6-K filing with the United States Securities and Exchange Commission. The Form 6-K is also incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3.
RedHill Biopharma Ltd. has announced the postponement of its Extraordinary General Meeting of Shareholders, which was originally scheduled for March 20, 2024. The adjournment was due to the absence of the required legal quorum. The meeting has been rescheduled to take place the following day, March 21, 2024, at 3:00 p.m. Israel time at the company's office in Tel Aviv. This information was disclosed in a Form 6-K filing with the United States Securities and Exchange Commission. The Form 6-K is also incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.